Biotech company enters million-dollar contract with US government

Meabco has managed to get through the eye of the needle at the governmental US health institute NIAID, and will receive DKK 40 million (USD 5.9 million) for the development of its treatment for radiation damage. Now, the company wants to raise fresh capital.

Damage from radiation therapy is one indication for Meabco's treatment. Photo: Klaus Holsting

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try MedWatch for 14 days.

Get a trial subscription here.

Do you want a trial subscription with multiple users for yourself and your colleagues?

Read more about your options and find the contact information to our sales team here.

Related articles